Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Namodenoson

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Can-Fite Advances Pancreatic Cancer Drug Study
    Can-Fite Advances Pancreatic Cancer Drug Study

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293853/0/en/following-positive-phase-2a-pancreatic-cancer-data-can-fite-advances-namodenoson-into-phase-2b-combination-study-with-immunotherapy.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Can-Fite's Namodenoson Shows Positive Phase 2A Results
    Can-Fite's Namodenoson Shows Positive Phase 2A Results

    30 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/30/3284876/0/en/can-fite-reports-positive-phase-2a-data-with-namodenoson-in-pancreatic-cancer-35-of-patients-remain-on-therapy-including-one-beyond-16-months.html

    GLOBENEWSWIRE
    30 Apr 2026
    Share Share
    Can-Fite Secures Israeli Patent for Namodenoson Anti-Obesity Use
    Can-Fite Secures Israeli Patent for Namodenoson Anti-Obesity Use

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257054/0/en/Can-Fite-Expands-Namodenoson-anti-Obesity-Franchise-with-Israeli-Patent-Allowance.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Can-Fite's Namodenoson Succeeds in Ph 2A Pancreatic Cancer Study
    Can-Fite's Namodenoson Succeeds in Ph 2A Pancreatic Cancer Study

    04 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/04/3249198/0/en/Can-Fite-s-Namodenoson-Successfully-Meets-Primary-Endpoint-in-Phase-2a-Pancreatic-Cancer-Study.html

    GLOBENEWSWIRE
    04 Mar 2026
    Share Share
    Can-Fite Granted Canadian Patent For Namodenoson As Anti-Obesity
    Can-Fite Granted Canadian Patent For Namodenoson As Anti-Obesity

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234404/0/en/Can-Fite-Receives-Canadian-Patent-Allowance-for-Namodenoson-as-an-Anti-Obesity-Therapy.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    Cirrhosis Patient Get Liver Transplant After Namodenoson
    Cirrhosis Patient Get Liver Transplant After Namodenoson

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232840/0/en/Can-Fite-Patient-with-Decompensated-Liver-Cirrhosis-Successfully-Undergoes-Liver-Transplantation-Following-Treatment-with-Namodenoson.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.